clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Chlamydial Pneumonia D061387 2 associated lipids
Sacroiliitis D058566 1 associated lipids
Plaque, Atherosclerotic D058226 7 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Upper Extremity Deep Vein Thrombosis D056824 1 associated lipids
Leprosy, Paucibacillary D056005 2 associated lipids
Extensively Drug-Resistant Tuberculosis D054908 1 associated lipids
Buruli Ulcer D054312 1 associated lipids
Immune Reconstitution Inflammatory Syndrome D054019 1 associated lipids
Renal Insufficiency D051437 8 associated lipids
Desulfovibrionaceae Infections D045824 5 associated lipids
Chlamydophila Infections D023521 4 associated lipids
Epilepsy, Partial, Motor D020938 1 associated lipids
Central Nervous System Protozoal Infections D020808 3 associated lipids
Neurotoxicity Syndromes D020258 34 associated lipids
Genetic Predisposition to Disease D020022 24 associated lipids
alpha 1-Antitrypsin Deficiency D019896 3 associated lipids
Tooth, Nonvital D019553 2 associated lipids
Gingival Overgrowth D019214 7 associated lipids
Carcinoma, Lewis Lung D018827 22 associated lipids
Cryptogenic Organizing Pneumonia D018549 3 associated lipids
Ventricular Dysfunction, Left D018487 33 associated lipids
Soft Tissue Infections D018461 2 associated lipids
Pneumonia, Bacterial D018410 16 associated lipids
Cardiovascular Abnormalities D018376 2 associated lipids
Tuberculosis, Multidrug-Resistant D018088 6 associated lipids
Cytomegalovirus Retinitis D017726 2 associated lipids
Community-Acquired Infections D017714 8 associated lipids
Soft Tissue Injuries D017695 2 associated lipids
Periodontal Attachment Loss D017622 7 associated lipids
Kleine-Levin Syndrome D017593 1 associated lipids
Cutaneous Fistula D017577 1 associated lipids
Pityriasis Rosea D017515 3 associated lipids
Dermatitis, Phototoxic D017484 4 associated lipids
Skin Diseases, Bacterial D017192 8 associated lipids
Liver Failure, Acute D017114 11 associated lipids
IgA Deficiency D017098 2 associated lipids
AIDS-Related Opportunistic Infections D017088 9 associated lipids
Common Variable Immunodeficiency D017074 4 associated lipids
Meningitis, Bacterial D016920 6 associated lipids
Angiomatosis, Bacillary D016917 2 associated lipids
Gram-Negative Bacterial Infections D016905 16 associated lipids
Ureaplasma Infections D016869 5 associated lipids
Empyema, Pleural D016724 2 associated lipids
Still's Disease, Adult-Onset D016706 2 associated lipids
Purpura, Thrombocytopenic, Idiopathic D016553 4 associated lipids
Bronchial Hyperreactivity D016535 15 associated lipids
Helicobacter Infections D016481 21 associated lipids
Bacteremia D016470 9 associated lipids
Prosthesis-Related Infections D016459 7 associated lipids
Lymphoma, T-Cell, Cutaneous D016410 4 associated lipids
Eye Infections, Bacterial D015818 3 associated lipids
Eye Infections D015817 1 associated lipids
Eye Injuries, Penetrating D015807 2 associated lipids
Leprosy, Lepromatous D015440 2 associated lipids
Leprosy, Borderline D015439 3 associated lipids
Discitis D015299 2 associated lipids
Mycobacterium avium-intracellulare Infection D015270 4 associated lipids
Sexually Transmitted Diseases, Bacterial D015231 5 associated lipids
Wound Infection D014946 12 associated lipids
Whooping Cough D014917 6 associated lipids
Uveitis, Anterior D014606 11 associated lipids
Urticaria D014581 13 associated lipids
Urination Disorders D014555 9 associated lipids
Urinary Tract Infections D014552 11 associated lipids
Urethritis D014526 9 associated lipids
Ureteral Obstruction D014517 10 associated lipids
Ureteral Diseases D014515 3 associated lipids
Typhoid Fever D014435 2 associated lipids
Tuberculosis, Spinal D014399 1 associated lipids
Tuberculosis, Pulmonary D014397 18 associated lipids
Tuberculosis, Ocular D014392 1 associated lipids
Tuberculosis, Avian D014379 2 associated lipids
Tuberculosis D014376 20 associated lipids
Tooth Discoloration D014075 7 associated lipids
Tenosynovitis D013717 3 associated lipids
Syphilis D013587 6 associated lipids
Synovitis D013585 15 associated lipids
Surgical Wound Infection D013530 7 associated lipids
Stomach Ulcer D013276 75 associated lipids
Stomach Neoplasms D013274 24 associated lipids
Stomach Diseases D013272 7 associated lipids
Sporotrichosis D013174 3 associated lipids
Splenic Diseases D013158 5 associated lipids
Skin Ulcer D012883 6 associated lipids
Skin Neoplasms D012878 12 associated lipids
Skin Diseases, Infectious D012874 7 associated lipids
Sinusitis D012852 9 associated lipids
Shock, Septic D012772 11 associated lipids
Serositis D012700 1 associated lipids
Scrub Typhus D012612 3 associated lipids
Rosacea D012393 13 associated lipids
Rodent Diseases D012376 4 associated lipids
Rickettsia Infections D012282 5 associated lipids
Rhabdomyolysis D012206 9 associated lipids
Radiation Injuries D011832 14 associated lipids
Pyelonephritis D011704 5 associated lipids
Psychoses, Substance-Induced D011605 7 associated lipids
Psychophysiologic Disorders D011602 3 associated lipids
Psoriasis D011565 47 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Kunin M et al. Mycobacterium chelonae peritonitis in peritoneal dialysis. Literature review. 2014 Eur. J. Clin. Microbiol. Infect. Dis. pmid:24569948
Fan Y et al. High and low doses of clarithromycin treatment are associated with different clinical efficacies and immunomodulatory properties in chronic rhinosinusitis. 2014 J Laryngol Otol pmid:24555753
Hanson KE et al. Rapid molecular detection of inducible macrolide resistance in Mycobacterium chelonae and M. abscessus strains: a replacement for 14-day susceptibility testing? 2014 J. Clin. Microbiol. pmid:24554745
Almeida N et al. Triple therapy with high-dose proton-pump inhibitor, amoxicillin, and doxycycline is useless for Helicobacter pylori eradication: a proof-of-concept study. 2014 Helicobacter pmid:24506175
Tan X and Song Z Human saliva-based quantitative monitoring of clarithromycin by flow injection chemiluminescence analysis: a pharmacokinetic study. 2014 Appl. Biochem. Biotechnol. pmid:24166104
Kakuda TN et al. Pharmacokinetic evaluation of the interaction between etravirine and rifabutin or clarithromycin in HIV-negative, healthy volunteers: results from two Phase 1 studies. 2014 J. Antimicrob. Chemother. pmid:24155058
Seung KJ et al. Salvage therapy for multidrug-resistant tuberculosis. 2014 Clin. Microbiol. Infect. pmid:23991934
Yakoob J et al. Comparison of antimicrobial activity of zinc chloride and bismuth subsalicylate against clinical isolates of Helicobacter pylori. 2014 Microb. Drug Resist. pmid:23844851
Markert C et al. Clarithromycin substantially increases steady-state bosentan exposure in healthy volunteers. 2014 Br J Clin Pharmacol pmid:23738582
Kathariya R et al. Evaluation of subgingivally delivered 0.5% clarithromycin as an adjunct to nonsurgical mechanotherapy in the management of chronic periodontitis: a short-term double blinded randomized control trial. 2014 J Investig Clin Dent pmid:23097216
Furuta T et al. Effect of dosing schemes of amoxicillin on eradication rates of Helicobacter pylori with amoxicillin-based triple therapy. 2014 J Clin Pharmacol pmid:24122836
Shahbazi Niaz M et al. Investigation into physical-chemical variables affecting the manufacture and dissolution of wet-milled clarithromycin nanoparticles. 2014 Pharm Dev Technol pmid:24093825
Bjerre M et al. Osteoprotegerin independently predicts mortality in patients with stable coronary artery disease: the CLARICOR trial. 2014 Scand. J. Clin. Lab. Invest. pmid:25026506
Khoshnood A et al. Replacement of clarithromycin with azithromycin in triple therapy regimens for the eradication of Helicobacter pylori: A randomized clinical trial. 2014 J Med Life pmid:25408735
Campanale M et al. Nickel free-diet enhances the Helicobacter pylori eradication rate: a pilot study. 2014 Dig. Dis. Sci. pmid:24595654
Svanström H et al. Use of clarithromycin and roxithromycin and risk of cardiac death: cohort study. 2014 BMJ pmid:25139799
Giamarellos-Bourboulis EJ et al. Effect of clarithromycin in patients with suspected Gram-negative sepsis: results of a randomized controlled trial. 2014 J. Antimicrob. Chemother. pmid:24292991
Zhao Y and Hu ZY Physiologically based pharmacokinetic modelling and in vivo [I]/K(i) accurately predict P-glycoprotein-mediated drug-drug interactions with dabigatran etexilate. 2014 Br. J. Pharmacol. pmid:24283665
Loreto ES et al. New insights into the in vitro susceptibility of Pythium insidiosum. 2014 Antimicrob. Agents Chemother. pmid:25223997
Harvey E and Varatharaj A Round pneumonia. 2014 QJM pmid:23708793
Tümgör G et al. Comparison of standard and standard plus vitamin E therapy for Helicobacter pylori eradications in children. 2014 Turk J Gastroenterol pmid:25910378
Çiftci İH et al. Comparison of FISH, RFLP and agar dilution methods for testing clarithromycin resistance of Helicobacter pylori. 2014 Turk J Gastroenterol pmid:25910373
Tsovolou EC et al. Effect of clarithromycin in experimental empyema by multidrug-resistant Pseudomonas aeruginosa. 2014 APMIS pmid:23656439
Yamada K et al. Azithromycin inhibits MUC5AC induction via multidrug-resistant Acinetobacter baumannii in human airway epithelial cells. 2014 Pulm Pharmacol Ther pmid:24910464
Patsche CB et al. Disseminated Mycobacterium celatum disease with prolonged pulmonary involvement. 2014 Int. J. Infect. Dis. pmid:25008771
Jesus FP et al. In vitro synergism observed with azithromycin, clarithromycin, minocycline, or tigecycline in association with antifungal agents against Pythium insidiosum. 2014 Antimicrob. Agents Chemother. pmid:25001300
Wu JY et al. Evidence-based recommendations for successful Helicobacter pylori treatment. 2014 Expert Rev Gastroenterol Hepatol pmid:24410470
Díaz Cuevas Z et al. [Nodular skin lesions in a patient with rheumatoid arthritis under therapy with anti-tumor necrosis factor-α]. 2014 Med Clin (Barc) pmid:23877097
Jung YS et al. [Trends in the eradication rates of Helicobacter pylori infection in Daegu and Gyeongsangbuk-do, Korea: multicenter study over 13 years]. 2014 Korean J Gastroenterol pmid:24561694
Vanderpas J et al. Follow-up of Helicobacter pylori infection in children over two decades (1988-2007): persistence, relapse and acquisition rates. 2014 Epidemiol. Infect. pmid:23809783
Koh S et al. Visualization of the meibomian glands by means of noncontact mobile-type meibography (Meibopen) in a 16-year-old girl with unilateral marginal staphylococcal keratitis. 2014 J AAPOS pmid:24568999
Ke AB et al. Itraconazole and clarithromycin as ketoconazole alternatives for clinical CYP3A inhibition studies. 2014 Clin. Pharmacol. Ther. pmid:24747234
Ghosh N et al. Clarithromycin overcomes resistance to lenalidomide and dexamethasone in multiple myeloma. 2014 Am. J. Hematol. pmid:24723438
Mendu ML and Waikar SS Drug-drug interactions and acute kidney injury: caveat prescriptor. 2014 Am. J. Kidney Dis. pmid:24820318
Gisbert JP et al. Third-line rescue therapy with bismuth-containing quadruple regimen after failure of two treatments (with clarithromycin and levofloxacin) for H. pylori infection. 2014 Dig. Dis. Sci. pmid:24126798
Maurer FP et al. Erm(41)-dependent inducible resistance to azithromycin and clarithromycin in clinical isolates of Mycobacterium abscessus. 2014 J. Antimicrob. Chemother. pmid:24500188
Tranos P et al. Bilateral diffuse iris atrophy after the use of oral clarithromycin. 2014 Cutan Ocul Toxicol pmid:23763291
Kuroda H et al. [Three cases of lenalidomide-resistant IgA myeloma for which a response was regained after the addition of clarithromycin]. 2014 Gan To Kagaku Ryoho pmid:25248908
Farley R et al. Antibiotics for bronchiolitis in children under two years of age. 2014 Cochrane Database Syst Rev pmid:25300167
Methaneethorn J et al. A pharmacokinetic drug-drug interaction model of simvastatin and clarithromycin in humans. 2014 Conf Proc IEEE Eng Med Biol Soc pmid:25571290
Hajaghamohammadi A et al. Low dose furazolidone for eradication of H- pylori instead of clarithromycin: a clinical trial. 2014 Glob J Health Sci pmid:25560342
Iwanczak B et al. Genotypic and clinical differences of seropositive Helicobacter pylori children and adults in the Polish population. 2014 J. Physiol. Pharmacol. pmid:25554984
Rakici H et al. Comparison of levofloxacin- and moxifloxacin-based triple therapies with standard treatment in eradication of Helicobacter pylori as first-line therapy. 2014 Digestion pmid:25547786
Karamanolis GP et al. The evolution of Helicobacter pylori antibiotics resistance over 10 years in Greece. 2014 Digestion pmid:25531953
Hemphill A et al. Treatment of echinococcosis: albendazole and mebendazole--what else? 2014 Parasite pmid:25526545
Kawai T et al. Changes in the first line Helicobacter pylori eradication rates using the triple therapy-a multicenter study in the Tokyo metropolitan area (Tokyo Helicobacter pylori study group). 2014 J. Gastroenterol. Hepatol. pmid:25521730
Kim SY et al. [Ten day concomitant therapy is superior to ten day sequential therapy for Helicobacter pylori eradication]. 2014 Korean J Gastroenterol pmid:25420735
Mustafa G and Necati B Clarithromycin-associated rhabdomyolysis in an infant. 2014 J Clin Rheumatol pmid:25417692
Hashim H et al. Eradication of Helicobacter pylori infection improves levodopa action, clinical symptoms and quality of life in patients with Parkinson's disease. 2014 PLoS ONE pmid:25411976
Wang B et al. Standard triple therapy for Helicobacter pylori infection in China: a meta-analysis. 2014 World J. Gastroenterol. pmid:25356059
Yangco BG et al. Is primary mycobacterium avium complex prophylaxis necessary in patients with CD4 <50 cells/μL who are virologically suppressed on cART? 2014 AIDS Patient Care STDS pmid:24833016
Martos M et al. Clarithromycin for first-line treatment of Helicobacter pylori infection after culture in high-resistance regions. 2014 Eur J Gastroenterol Hepatol pmid:25229983
Veraldi S et al. Treatment of sporotrichoid fish tank granuloma with pulsed clarithromycin. 2014 Dermatology (Basel) pmid:25228273
Phillips RO et al. Reply to "compliance with antimicrobial therapy for buruli ulcer". 2014 Antimicrob. Agents Chemother. pmid:25225343
Klis S et al. Compliance with antimicrobial therapy for buruli ulcer. 2014 Antimicrob. Agents Chemother. pmid:25225342
Mitui M et al. Novel Helicobacter pylori sequencing test identifies high rate of clarithromycin resistance. 2014 J. Pediatr. Gastroenterol. Nutr. pmid:25222804
Gold BD Resistance testing for Helicobacter pylori infection: is it finally ready for prime time? 2014 J. Pediatr. Gastroenterol. Nutr. pmid:25222802
Morakul B et al. Dissolution enhancement and in vitro performance of clarithromycin nanocrystals produced by precipitation-lyophilization-homogenization method. 2014 Eur J Pharm Biopharm pmid:25201298
Peng YC et al. Clarithromycin modulates Helicobacter pylori-induced activation of nuclear factor-κB through classical and alternative pathways in gastric epithelial cells. 2014 Clin. Exp. Med. pmid:23129507
Parekh TM et al. Hypoglycemia after antimicrobial drug prescription for older patients using sulfonylureas. 2014 JAMA Intern Med pmid:25179404
Kutluk G et al. Sequential therapy versus standard triple therapy for Helicobacter pylori eradication in children: any advantage in clarithromycin-resistant strains? 2014 Eur J Gastroenterol Hepatol pmid:25171023
Higashi F et al. Additional treatment with clarithromycin reduces fever duration in patients with influenza. 2014 Respir Investig pmid:25169846
de Boer EM et al. [Antibiotic resistance of Helicobacter pylori: prevalence in one region in the southern Netherlands and implications for treatment]. 2014 Ned Tijdschr Geneeskd pmid:25159698
Elkhatib W and Noreddin A Efficacy of ciprofloxacin-clarithromycin combination against drug-resistant Pseudomonas aeruginosa mature biofilm using in vitro experimental model. 2014 Microb. Drug Resist. pmid:25050970
Ohe M and Bohgaki T Successful treatment with clarithromycin for patients with polymyalgia rheumatica. 2014 Korean J. Intern. Med. pmid:25045305
Martin JH and Coombes I Mortality from common drug interactions systems, knowledge and clinical reasoning to optimise prescribing. 2014 Intern Med J pmid:25041768
Bansal S and Chhibber S Phytochemical-induced reduction of pulmonary inflammation during Klebsiella pneumoniae lung infection in mice. 2014 J Infect Dev Ctries pmid:25022293
Fouka E et al. Low-dose clarithromycin therapy modulates Th17 response in non-cystic fibrosis bronchiectasis patients. 2014 Lung pmid:25016929
Lambert D et al. Gastritis due to Helicobacter pylori, an unusual cause of chronic diarrhoea in HIV infected patients. 2014 Med Mal Infect pmid:25015308
Dalbøge CS et al. Pharmacokinetic variability of clarithromycin and differences in CYP3A4 activity in patients with cystic fibrosis. 2014 J. Cyst. Fibros. pmid:24035278
Teh X et al. Functional and molecular surveillance of Helicobacter pylori antibiotic resistance in Kuala Lumpur. 2014 PLoS ONE pmid:25003707
Lyons J et al. An unusual lung mass post stem cell transplantation. 2014 Transpl Infect Dis pmid:24995624
Lee JW et al. A comparison between 15-day sequential, 10-day sequential and proton pump inhibitor-based triple therapy for Helicobacter pylori infection in Korea. 2014 Scand. J. Gastroenterol. pmid:24988873
Liu CP et al. NO-releasing xanthine KMUP-1 bonded by simvastatin attenuates bleomycin-induced lung inflammation and delayed fibrosis. 2014 Pulm Pharmacol Ther pmid:23518214
Glatz M and Muellegger RR Drug-associated aquagenic wrinkling of the palms in an atopic male patient. 2014 BMJ Case Rep pmid:24903725
DiCicco M et al. In vitro synergism of fosfomycin and clarithromycin antimicrobials against methicillin-resistant Staphylococcus pseudintermedius. 2014 BMC Microbiol. pmid:24886369
Noonan KA et al. Targeting immune suppression with PDE5 inhibition in end-stage multiple myeloma. 2014 Cancer Immunol Res pmid:24878583
Gong EJ et al. Meta-analysis of first-line triple therapy for helicobacter pylori eradication in Korea: is it time to change? 2014 J. Korean Med. Sci. pmid:24851029
Jeon HK and Kim GH Does standard triple therapy still have a role in first-line Helicobacter pylori eradication in Korea? 2014 J. Korean Med. Sci. pmid:24851014
Rasheed F et al. Analysis of clinical isolates of Helicobacter pylori in Pakistan reveals high degrees of pathogenicity and high frequencies of antibiotic resistance. 2014 Helicobacter pmid:24827414
Wang Y et al. Efficacy and safety of ecabet sodium as an adjuvant therapy for Helicobacter pylori eradication: a systematic review and meta-analysis. 2014 Helicobacter pmid:24826809
Pan-In P et al. Ethyl cellulose nanoparticles: clarithomycin encapsulation and eradication of H. pylori. 2014 Carbohydr Polym pmid:24815396
Ichihara A et al. Case of disseminated cutaneous Mycobacterium chelonae infection mimicking cutaneous vasculitis. 2014 J. Dermatol. pmid:24801916
Togami K et al. Involvement of intestinal permeability in the oral absorption of clarithromycin and telithromycin. 2014 Biopharm Drug Dispos pmid:24801141
Bernut A et al. In vivo assessment of drug efficacy against Mycobacterium abscessus using the embryonic zebrafish test system. 2014 Antimicrob. Agents Chemother. pmid:24798271
Adebisi AO and Conway BR Lectin-conjugated microspheres for eradication of Helicobacter pylori infection and interaction with mucus. 2014 Int J Pharm pmid:24792977
Bolhuis MS et al. In vitro synergy between linezolid and clarithromycin against Mycobacterium tuberculosis. 2014 Eur. Respir. J. pmid:24791826
Lee SH et al. Detection and assessment of clarithromycin inducible resistant strains among Korean Mycobacterium abscessus clinical strains: PCR methods. 2014 J. Clin. Lab. Anal. pmid:24652818
Binh TT et al. Discovery of novel mutations for clarithromycin resistance in Helicobacter pylori by using next-generation sequencing. 2014 J. Antimicrob. Chemother. pmid:24648504
Karaolia P et al. Reduction of clarithromycin and sulfamethoxazole-resistant Enterococcus by pilot-scale solar-driven Fenton oxidation. 2014 Sci. Total Environ. pmid:24012892
Tursi A et al. Decreasing efficacy of the standard seven-day triple therapy containing amoxycillin and clarithromycin in curing Helicobacter pylori infection in clinical setting in Italy: a 10-year follow-up study. 2014 Panminerva Med pmid:24637473
Wei Z et al. Rome III criteria cannot distinguish patients with chronic gastritis from those functional dyspepsia patients. 2014 Helicobacter pmid:24617669
Rizzo A et al. Antimicrobial effect of natural polyphenols with or without antibiotics on Chlamydia pneumoniae infection in vitro. 2014 Microb. Drug Resist. pmid:23952319
Wu JY et al. Feasibility of shortening 14-day hybrid therapy while maintaining an excellent Helicobacter pylori eradication rate. 2014 Helicobacter pmid:24612093
Settin A et al. Cure rate of Helicobacter pylori infection in Egyptian children related to CYP2C19 gene polymorphism. 2014 Indian J Gastroenterol pmid:24610583
Garza-González E et al. A review of Helicobacter pylori diagnosis, treatment, and methods to detect eradication. 2014 World J. Gastroenterol. pmid:24587620
Okame M et al. Complete regression of early-stage gastric diffuse large B-cell lymphoma in an HIV-1-infected patient following Helicobacter pylori eradication therapy. 2014 Clin. Infect. Dis. pmid:24585569
Mark TM et al. Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myeloma. 2014 Leuk. Lymphoma pmid:24576165
Zhang J et al. Ocular penetration and pharmacokinetics of topical clarithromycin eye drops to rabbits. 2014 J Ocul Pharmacol Ther pmid:24199739
Takazono T et al. Paradoxical response to disseminated non-tuberculosis mycobacteriosis treatment in a patient receiving tumor necrosis factor-α inhibitor: a case report. 2014 BMC Infect. Dis. pmid:24576098